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Machine learning methods have frequently been used in early stage diagnosis at the 
proteomic level, such as the MHC binding peptides prediction and biomarkers selection 
for metabonomics. Although many computational methods have been designed for such 
studies, it is necessary to develop more stable and smart system to improve predictive 
performance. Support vector machine, an artificial intelligence technique, demonstrates 
remarkable generalization performance. Two groups of MHC binding peptides and two 
bladder cancer metabonomics datasets with different number of metabolites has been 
investigated by support vector machine and other machine learning methods. Recursive 
feature elimination, an effective feature selection algorithm, has also been applied to 
investigate the metabonomics data. The results of MHC binding peptide study showed 
that the prediction system can achieve satisfactory performance by constructing the 
model with sufficient generated non-binding peptides. The second study on 
metabonomics prediction suggested that metabolites biomarkers can be effectively 
selected from the metabonomics dataset by support vector machine-recursive feature 
elimination method.  
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Support vector machines (SVMs) are a group of supervised learning methods that can be 
applied to classification or regression problems. The support vector (SV) algorithm is a 
nonlinear generalization of the Generalized Portrait algorithm developed in the early 
60’s.1,2 In the past few decades, SVM showed excellent performance in many real-world 
applications such text categorization, hand-written character recognition, image 
classification and etc. With the advent of the genomic, proteomic and metabonomics era, 
the availability of human genome provides an opportunity to elucidate the genetic basis 
of biological processes and human diseases. However, the huge amount of data requires 
the development of high-throughput analysis tools and powerful computational capacity 
to facilitate the data analysis. Facing these challenges, bioinformatics has created many 
techniques, of which SVM as one of them. In the following sections, the increasing 
applications of SVM in bioinformatics, specifically genomics, proteomics and 
metabonomics, are reviewed. 
1.1 Applications of SVM in bioinformatics 
1.1.1 Applications of SVM in genomics 
The Human Genome Project (HGP) was launched in 1989 with the initial goal of 
producing a draft sequence of the human genome. A working draft of genome was 
announced in 2000 and completed version in 2003. But knowledge of the genomic 
sequence is just the first step towards the understanding of the development and functions 
of organisms. The next key landmark will be an overview of the characteristics and 
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activities of the proteins encoded in the genes. Since not all genes are expressed at the 
same time, a further question is which genes are active under which circumstances. One 
of the immediate goals of comparative genomics is the understanding of the evolutionary 
trajectories of genes and integrating them into plausible evolutionary scenarios for entire 
genomes. A prerequisite for this process is a phylogenetic classification of genes. 
The fast progress in genome sequencing projects calls for rapid, reliable and accurate 
functional assignments of gene products. Genome annotation
3
 enables the structural and 
functional understanding of genome. Computational analysis has been extensively 
explored to perform automatic annotation to co-exist with and complement mutual 
annotation. The basic level of annotation is annotating genomes based on BLAST based 
similarities. Nowadays a lot more additional information is added to the annotation 
platform including genome context information, similarity scores, experimental data and 
integrations of other resources and a variety of software tools have been developed to 
annotate sequences on a large scale. In recent years, the application of SVMs in genome 
annotation was aroused.
4-8
 These automated annotation systems develop binary classifiers 
based on sequence data and assign these sequences to certain Gene Oncology (GO) 
terms.
4-8
 Compared to other existing genome annotation systems, these SVMs based 




With the accomplishment of HGP, genome-wide association studies (GWAS) are largely 
launched to derive gene signatures to determine common and complex diseases such as 




 In 2005, a GWAS found an 
association between ARMD and a variation in the gene of complement factor H (CFH). 
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Together with four other variants, these genes can predict half the risk of ARMD between 
siblings and make it the earliest and most successful example of GWAS.
9
 In 2007, a 
GWAS found an association between type 2 diabetes (T2B) and a variation in several 
single nucleotide polymorphisms (SNPs) in the genes TCF7L2, SLC30A8 and others.
10
 
In recent years, SVMs have been applied to detect the variations associated with various 
diseases. Listgarten et al. explored combinations of SNPs from 45 genes and detected 
their potential relevance to breast cancer etiology in 174 patients and accuracy of 69% 
was obtained by using SVMs as the learning algorithm.
11
 They concluded that multiple 
SNPs from different genes over distant parts of the genome are better at identifying breast 
cancer patients than any single SNP alone. Waddell et al. have applied SVMs to predict 
the susceptibility to multiple myeloma.
12
 Their work had 71% accuracy on a dataset 
containing 40 cases and 40 controls.
12
 In 2009, by using several machine learning 
techniques including SVM, Uhmn et al. predicted patients' susceptibility to chronic 
hepatitis from SNPs.
13
 More recently, Ban et al. investigated 408 SNPs in 87 genes 
involved in major T2D related pathways in 462 T2D patients and 456 healthy controls 
using SVM and achieved a 65.3% prediction rate with a combination of 14 SNPs in 12 
genes.
14
 As the high-throughput technology for genome-wide SNPs improves, it is likely 
that a much higher prediction rate with biologically more interesting combination of 
SNPs can be acquired and this will further benefit future drug discovery efforts and 
choosing of proper treatment strategies. 
1.1.2 Applications of SVM in proteomics 
After genomics, proteomics is considered the next step in the study of biological systems. 
It is much more complicated than genomics mostly because while an organism's genome 
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is more or less constant, the proteome differs from cell to cell and from time to time. This 
is because distinct genes are expressed in distinct cell types. This means that even the 
basic set of proteins which are produced in a cell needs to be determined. In the past, this 
was done by mRNA analysis but it was found not to correlate with protein content.
15,16
 It 
is now known that mRNA is not always translated into protein, and the amount of protein 
produced for a given amount of mRNA depends on the gene it is transcribed from and on 
the current physiological state of the cell. Besides, not only does the translation from 
mRNA cause differences, many proteins are also subjected to a wide variety of chemical 
modifications after translation. Many of these post-translational modifications, such as 
phosphorylation, ubiquitination, methylation, acetylation, glycosylation, oxidation, 
nitrosylation and etc., are critical to the protein's function.  
Despite the difficulties in proteomic studies, scientists are still interested in proteomics 
because it gives a much better understanding of the functions of an organism than 
genomics. Functional clues contained in the amino acid sequence of proteins and 
peptides
17-20
 have been extensively explored for computer prediction of protein function 
and functional peptides. A particular challenge is to derive functional properties from 
sequences that show low or no homology to proteins of known function. 
Recently, SVMs have been explored for functional study of proteins and peptides by 
determining whether their amino acid sequence derived properties conform to those of 
known proteins of a specific functional class
21-25
. The advantage of this approach is that 
more generalized sequence-independent characteristics can be extracted from the 
sequence derived structural and physicochemical properties of the multiple samples that 
share common functional profiles irrespective of sequence similarity. These properties 
5 
 
can be used to derive classifiers
19-30
 for predicting other proteins that have the same 
functional or interaction profiles. 
The task of predicting the functional class of a protein or peptide can be considered as a 
two-class (positive class and negative class) classification problem for separating 
members (positive class) and non-members (negative class) of a functional or interaction 
class. SVM and other well established two-class classification-based machine learning 
methods can then be applied for developing an artificial intelligence system to classify a 
new protein or peptide into the member or non-member class, which is predicted to have 
a functional or interaction profile if it is classified as a member.  
The reported prediction accuracies for class members (P+) and non-members (P–) of 
SVM for predicting protein functional classes are in the range of 25.0%~100.0% and 
69.0%~100.0%, with the majority concentrated in the range of 75%~95% and 
80%~99.9% respectively
21-24,31-45
. Based on these reported results, SVM generally shows 
a certain level of capability for predicting the functional class of proteins and 
protein-protein interactions. In many of these reported studies, the prediction accuracy for 
the non-members appears to be better than that for the members. The higher prediction 
accuracy for non-members likely results from the availability of more diverse set of 
non-members than that of members, which enables SVM to perform a better statistical 
learning for recognition of non-members. 
Prediction of protein-binding peptides have primarily been focused on MHC-binding 
peptides,
27
 the reported P+ and P– values for MHC binding peptides are in the range of 
75.0%~99.2% and 97.5%~99.9%, with the majority concentrated in the range of 
6 
 
93.3%~95.0% and 99.7%~99.9% respectively.
46-48
 These studies have demonstrated that, 
apart from the prediction of protein functional classes, SVM is equally useful for 
predicting protein-binding peptides and small molecules. 
From the above reported results, it can be easily concluded that SVM shows promising 
potential for a wide spectrum of protein and peptide classes including some of the low- 
and non-homologous proteins. This method can thus be explored as a potential tool to 
complement alignment-based, clustering-based, and structure-based methods for 
predicting protein function and interactions. 
1.1.3 Applications of SVM in metabonomics 
Metabonomics is the comprehensive and quantitative assessment of low molecular 
weight analytes (<1500Da) that define the metabolic status of an organism under a given 
condition.
49
 In complementation with genomics and proteomics, the direct measurement 
of metabolite expression is essential in the systematic understanding of biological process. 
Metabolomics is increasingly enjoying widespread applications in areas such as 
functional genomics, identification of the onset and progression of disease, 
pharmacogenomics, nutrigenomics, and system biology.
50-53
  
Because of its sensitivity and coverage, mass spectrometry (MS) is a favorable 
technology for metabolomics study. One major bottleneck for current MS-based 
metabolomics is the identification of metabolites. To identify the correct metabolite from 
a large volume of MS/MS spectra, a proper comparison or scoring scheme is needed. In 
machine learning, SVMs are widely considered to represent the state of the art in 
classification accuracy. Recently, SVMs have been applied to the supervised 
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classification of cancer versus control sample sets from MS data.
54-63
 Xue et al. 
investigated the serum metabolic difference between hepatocellular carcinoma (HCC) 
male patients and normal male subjects by stepwise discriminant analysis (SDA) and 
SVM based on gas chromatography (GC)/MS data.
61
 The resultant diagnostic model 
could discriminate between HCC patients and normal subjects with 20-fold cross 
validation classifying accuracy of 75% and error count estimate for each group of 0%.
61
 
Henneges et al. constructed breast cancer predictive models by profiling of urinary RNA 
metabolites using SVM-based feature selection from data obtained from liquid 
chromatography ion trap (LC-IT) MS, and had classification sensitivity and specificity of 
83.5% and 90.6% respectively.
63
 The performance of SVM for the classification of liquid 
chromatography/time-of-flight (LC/TOF) MS metabolomics data focusing on 
recognizing combinations of potential metabolic ovarian cancer diagnostic biomarkers 
was evaluated by Guan et al.
54
 The classification of the serum sample test set was 90% 
accurate, which suggests that the developed approach might lead to the development of 
an accurate and reliable metabolomics-based approach for detecting ovarian cancer.
54
 
More recently, Zhou et al. collected MS/MS spectra for 21 metabolites from both 
in-house data and publicly available data from the Human Metabolite Database (HMDB) 
and utilized SVM to incorporate both peak and profile similarity measures for spectral 
matching. The models had accuracies and F-measure ranging from 94.6%~96.3% and 
80.7%~85.1% respectively.
64
 By comparing the identification performance with other 
algorithms (NIST, MassBank and SpectraST) and the correlation method, it was observed 
that SVM can achieve 7% to 10% improvement on identification performance.
64
  
1.2 Underlying difficulties in using SVM 
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The performance of SVM critically depends on the diversity of samples in a training 
dataset and the appropriate representation of these samples. The datasets used in many of 
the reported studies are not expected to be fully representative of all of the proteins, 
peptides and small molecules with and without a particular functional and interaction 
profile. Various degrees of inadequate sampling representation likely affect, to a certain 
extent, the prediction accuracy of the developed statistical learning models. SVM is not 
applicable for proteins, peptides and small molecules with insufficient knowledge about 
their specific functional and interaction profile. Searching of the information about 
proteins, peptides and small molecules known to possess a particular profile and those 
that do not possess the profile is key to more extensive exploration of statistical learning 
methods for facilitating the study of functional and interaction profiles.  
In the datasets of some of the reported studies, there appears to be an imbalance between 
the number of samples having a profile and those without the profile. SVM method tends 
to produce feature vectors that push the hyper-plane towards the side with smaller 
number of data,
65
 which often lead to a reduced prediction accuracy for the class with a 
smaller number of samples or less diversity (usually members) than those of the other 
class (usually non-members). It is however inappropriate to simply reduce the size of 
non-members to artificially match that of members, since this compromises the diversity 
needed to fully represent all non-members. Computational methods for re-adjusting 
biased shift of hyper-plane are being explored.
66
 Application of these methods may help 
improving the prediction accuracy of SVM in the cases involving imbalanced data. 
While a number of descriptors have been introduced for representing proteins and 
peptides,
19,31,67,68
 most reported studies typically use only a portion of these descriptors. It 
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has been found that, in some cases, selection of a proper subset of descriptors is useful for 
improving the performance of SVM.
69-71
 Therefore, there is a need to explore different 
combination of descriptors and to select an optimum set of descriptors using feature 
selection methods.
69-71
 Efforts have also been directed at the improvement of the 
efficiency and speed of feature selection methods,
72
 which will enable a more extensive 
application of feature selection methods. Moreover, indiscriminate use of the existing 
descriptors, particularly those of overlapping and redundant descriptors, may introduce 
noise as well as extending the coverage of some aspects of these special features. Thus, it 
may be necessary to introduce new descriptors for the systems that have been described 
by overlapping and redundant descriptors. Investigations of cases of incorrectly predicted 
samples have also suggested that the currently-used descriptors may not always be 
sufficient for fully representing the structural and physicochemical properties of proteins, 
peptides and small molecules.
30,55,73




1.3 Objectives and organization of this thesis 
1.3.1 Objectives of this thesis 
The main objective of this thesis is to investigate and develop novel systems of support 
vector machine for –omics application. Two types of studies were included in this 
investigation. These are MHC binding prediction for proteomics level, and metabolites 
selection for metabonomics level. 
The first study is to explore an improved flexible prediction system for MHC binding 
prediction. Generally, there are several inevitable limitations of the current prediction 
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systems. First of all, most prediction systems were particularly designed for peptides with 
fixed lengths. Secondly, the dataset size of the existing systems, especially the training 
dataset of non-binders are not adequate for building a reliable prediction model. Thirdly, 
some of the prediction systems represented peptides not by the structural and 
physicochemical properties, but by sequence of peptides directly. Last but not least, most 
MHC binding prediction systems only cover a limited number of MHC alleles, which 
leads to a lack of statistically significant number of known peptides in the commonly 
studied length ranges. 
There are several feasible ways to alleviate the above problems. These include choosing a 
prediction algorithm which works for peptides with flexible lengths; representing the 
peptides with sequence-derived structural and physicochemical properties; and 
conducting the training data with sufficiently diverse set of non-binders. All of these 
improvements can be achieved in the studies by using support vector machine. According 
to previous studies, SVM has shown promising capability for prediction of specific 
functional group of flexible lengths with sequence-derived structural and 
physicochemical properties. Moreover, peptides in same specific functional group are 
generally diverse but share similar structural and physicochemical features. To some 
extents, the MHC binding peptides in specific alleles share similar characteristics, which 
mean they have similar structural and physicochemical features. Therefore, SVM is 
expected to be a potential eligible algorithm to be applied for predicting MHC binding 
and non-binding peptides. 
The second part of this thesis is to investigate a new approach of metabolites selection by 
using support vector machine feature selection system. The development of a new 
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approach of metabolites selection is one of the major topics in the area of data mining in 
metabonomics studies. It is important to find the marker metabolites responsible for 
disease reaction. This may help in early diagnosis and correct prediction of disease. The 
general workflow of data mining in metabonomics analysis can be found in Figure 1. 
There are two major sub-objectives for the second part of study. (1) Discovery of marker 
metabolites responsible for the distinction between groups of samples related to the 
specific interests. (2) Development the better metabolites selection methods by advanced 
machine learning algorithm. Compared with the traditional methods of metabolites 
selection, the new approach will be derived from the strategies of gene selection in 
microarray data. Several feature selection methods and algorithms (e.g.: SVM recursive 
feature elimination, forward/backward weighting methods based on Decision tree, Naïve 
Bayes kernel function and other traditional weighting methods) will be compared to 
determine their performance and usability for metabolite selection. 
12 
 







1.3.2 Organization of this thesis 
Chapter 1 introduces the history of SVMs and reviews their increasing applications in 
bioinformatics especially in genomics, proteomics and metabolomics.  
Chapter 2 describes in detail the mathematical theory of SVM as a combination of two 
main concepts: Maximal Margin Hyperplanes (also called Optimal Separating 
Hyperplanes) and kernel functions. The general criteria for evaluating the classifying 
performance are also introduced.  
Chapter 3 elucidated the real application of SVM in MHC binding prediction. Several 
SVM prediction systems were developed and evaluated for the multiple MHC alleles. 
The accuracies of these prediction systems were validated using fivefold cross validation. 
Chapter 4 elaborated the application of SVM for metabolites selection in metabonomics. 
Urine samples of 75 subjects of bladder cancers were investigated with the methods of 
metabonomics. The advances of SVM system in metabolites selection were demonstrated 
by comparison with several feature selection algorithms.  
Chapter 5 concludes the achievement and limitation of current work. Future works are 




2.1 Support vector machines (SVMs) method 
The process of training and using a SVM model for screening peptides based on their 
physicochemical property descriptors is schematically illustrated in Figure 2. SVM is 
based on the structural risk minimization principle of statistical learning theory,
74-79
 
which consistently shows outstanding classification performance, is less penalized by 
sample redundancy, and has lower risk for over-fitting.
80-82
  
2.1.1 Linear SVM 
In two-class problems, SVM aims to separate examples of two classes with the maximum 
hyper plane (Figure 3). Mathematically, the data is composed of n examples of two 
classes, denoted as 1 2{( , ), , ( , )}n nx y x y  , where 
N
ix R  is a vector in feature space 
and { 1, 1}iy     denotes its class. A hyper plane could be drawn to separate examples 
of one class (positive examples) from those of the other one (negative examples). The 
hyper plane is represented by 0w x b   , where w  is slope and b is bias. Thus the 
objective function of SVM changes to minimize Euclidean norm
2
w  with following 
limitations:  
1iw x b     for 1iy         (positive examples)               (1) 
1iw x b     for 1iy         (negative example)               (2) 
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Figure 3 Architecture of support vector machines 
 




According to which side those new instances locate, we can easily determine which class 
they belong to. So the decision function becomes , ( ) ( , )w bf x sign w x b    . 
Geometrically, all the points are divided into two regions by a hyper plane H. As shown 
in Figure 4, there are numerous ways through which a hyper plane can separate these 
examples. The objective of SVM is to choose the “optimal” hyper plane. As all new 
examples are supposed to be located under similar distribution as training examples, the 
hyper plane should be chosen such that small shifts of data do not result in fluctuations in 
prediction result. Therefore, the hyper plane that separates examples of two classes 
should have the largest margin, which is expected to possess the best generalization 
performance. Such hyper plane is called the Optimal Separating Hyper plane (OSH).
83
 
Examples locating on the margins are called support vectors, whose presentation 
determines the location of the hyper plane. OSH could be thus represented by a linear 
combination of support vectors. The margin ( , )i w b of a training point ix is defined as 
the distance between H and ix : 
( , ) ( )i iw b y w x b                             (3) 
and the margin of a set of vectors 1{ , , }nS x x is defined as the minimum distance 
between the hyper plane H to all the vectors in S : 
{ | 1} { | 1}
( , ) ( , )min min max
i
S i
x S x y x y
w x w x





                (4) 





Maximize: ( , )w b                             (5) 
Subject to: 
( , ) 0w b                                 (6) 
2
1w                                  (7) 




w                            (8) 
Subject to: 
1iw x b     for 1iy                          (9) 
1iw x b     for 1iy                         (10) 
This optimization problem could be efficiently solved by the Lagrange method. With the 
introduction of Lagrangian multipliers 0( 1,2,..., )i i n   , one for each of the inequality 
constraints, we obtain the Lagrangian: 
1
1




P i i i
i
L w b w w y w x b 

                    (11) 
This is a Quadratic Programming (QP) problem. We would have to minimize ( , , )PL w b   
with respect to w , b and simultaneously require that the derivatives of ( , , )PL w b   with 
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                        (12) 
By substituting these two equations into equation (11), the QP problem becomes the 
Wolfe dual of the optimization problem: 
1 , 1
1
( , , ) ( )
2
n n
D i i j i j i j
i i j
L w b y y x x  
 
                   (13) 








  and 0i  , 1,2, ,i n . 
The corresponding bias 0b  can be calculated as: 
 0 0 0{ | 1} { | 1}
1
( ) ( )
2
min max
x y x y
b w x w x
 
                      (14) 
This QP problem could be efficiently solved through several standard algorithms like 
Sequential Minimization Optimization
86
 or decomposition algorithms.
87
 
Once 0w and 0b  are determined, the hyper plane is readily drawn. The points for which 






2.1.2 Nonlinear SVM 
Many real-world problems are usually too complicated to be solved with linear classifiers. 
With the introduction of kernel techniques, input data could be mapped to a 
higher-dimension space, where a new linear classifier can be used to classify these 
examples (Figure 5). 
Figure 5 Mapping input space to feature space 
 
 
Let   denotes an implicit mapping function from input space to feature space F . Then 
all the previous equations are transformed by substituting input vector ix  and inner 
product ( , )ix x  with ( )ix  and kernel ( , )iK x x  respectively, where 
( , ) ( ) ( )i iK x x x x                           (15) 





( , , ) ( )
2
n n n
D i i j i j i j
i i j
L w b y y K x x  
  









  and 0i  , for 1,2, ,i n . The bias 0b  becomes  
0
{ | 1} { | 1}
1
[ ( , )] [ ( , )]
2
min maxi i i i i i
SV SV
x y x y
b y K x x y K x x 
 
 
   
 
             (17) 
and the decision function becomes 
0 0
1
( ) [ ( , ) ] [ ( , ) ]
n n
i i i i i i
i SV
f x sign y K x x b sign y K x x b 

               (18) 
Note that the mapping function   is never explicitly computed, which would 
significantly reduce the computation load. Another advantage is that the feature space 
may be infinitely dimensional, such as in the case of Gaussian kernel,
89
 where mapping 
function cannot be explicitly represented. A function could be used as a kernel function if 
and only if it satisfies Merce’s condition.90 Followings are well-known kernel functions: 
Polynomial ( , ) ( , 1) pk x z x z     
Sigmoid ( , ) tanh( , )k x z x z      
Radial basis function (RBF) 
2 2( , ) exp( / 2 )k x z x z     
In this work, RBF kernel is used due to its many advantages demonstrated in previous 
studies. Different SVM models could be developed by using different   values. It is 
thus necessary to scan a number of   values to find the best model, which is evaluated 
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by their performance on classification tasks. Figure 1 illustrates the schematic diagrams 
of the process of training and prediction of drug targets by SVM. Sequence-derived 
feature hi, pi, vi… represents such structural and physicochemical properties as 
hydrophobicity, polarizability, and volume. The calculation of the structural and 
physicochemical properties used for representing MHC binding peptides is described in 
Chapter 3 and the Recursive Feature Elimination (RFE) method used for metabolites 
prediction is introduced in Chapter 4. 
2.2 Performance evaluation 
The performance evaluation aims to find out whether an algorithm is able to be applied to 
novel data that have not been used to develop the prediction model, or measure the 
generalization capacity to recognize new examples from the same data domain.
91
 
In this study, several statistical measurements were explored, including sensitivity (SE), 
specificity (SP), positive prediction value (PPV), and overall prediction accuracy (Q). 
The formulas to calculate these measurements are listed as follows: 
)/( FNTPTPSE   
)/( FPTNTNSP   
)/( FPTPTPPPV   
)/()( FNFPTNTPTNTPQ   
where TP, FN, TN, and FP represent correctly predicted positive data, positive data 
incorrectly predicted as negative, correctly predicted negative data, and negative data 
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incorrectly predicted as positive respectively. Another measurement, Matthews 
correlation coefficient (MCC), was also used to evaluate the randomness of the 
prediction. 
))()()((/)( FNTNFPTNFPTPFNTPFNFPTNTPMCC   
where MCC ranges from -1 to 1. Negative values of MCC indicate disagreement between 
prediction and measurement, while positive values of MCC indicates agreement between 





3 MHC BINDING PREDCITION 
This work developed several prediction systems for 22 MHC Class I and 17 MHC Class 
II alleles by SVM. An original dataset without the pseudo non-binding peptides has been 
tested. All peptide of this dataset were collected from the database. The 29520 binder 
peptides and 24848 non-binder peptides were collected from IEDB have been tested with 
the five-fold cross validation. As a comparison, serial tests were conducted based on each 
allele. The pseudo non-binding peptides generated from the splitting proteins have been 
included in these tests. Fivefold cross validation has been applied to evaluate the 
performance of these prediction systems. 
3.1. Data Preparation 
Data collection from databases 
Binding peptides and non-binding peptides of 22 MHC class I and 17 MHC class II 
alleles were collected from 2 databases: IEDB (Immune Epitope Database 
www.immuneepitope.org/) and SYFPEITHI (www.syfpeithi.de). A total of 70692 MHC 
binding peptides were collected from these two databases. After removing the duplicated 
binders, there were 29520 peptides left. 93734 MHC non-binding peptides were collected 
from these two databases. After removing the duplicated non-binders, there were 24848 
peptides left. 
It had been discovered that the number of tested peptides can severely affected the 
model’s prediction performance, especially when the number is less than 150 92. Thus, 
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only alleles with more than 150 binding peptides had been chosen to be studied in this 
project, to ensure a good performance of the prediction model. 
There are 452, 5015, 856, 882, 796, 1176, 1134, 65, 308, 324, 226, 547, 209, 609, 517, 
488, 335, 526, 454, 252, 209, 1274, 339, 288, 254, 1993, 370, 874, 270, 238, 373, 240, 
221, 498, 236, 379, 150,254, 374 binders for class I and class II allele HLA-A*0101, 
HLA-A*0201, HLA-A*0202, HLA-A*0203, HLA-A*0206, HLA-A*0301, 
HLA-A*1101, HLA-A*2601, HLA-A*2902, HLA-A*3001, HLA-A*3002, 
HLA-A*3101, HLA-A*330, HLA-A*6801, HLA-A*6802, HLA-B*0702, HLA-B*0801, 
HLA-B*1501, HLA-B*3501, HLA-B*4402, HLA-A*11, HLA-A*2, HLA-DR*1, 
HLA-DR*4, HLA-DR*7, HLA-DRB1*0101, HLA-DRB1*0301, HLA-DRB1*0401, 
HLA-DRB1*0404, HLA-DRB1*0405, HLA-DRB1*0701, HLA-DRB1*0802, 
HLA-DRB1*0901, HLA-DRB1*1101, HLA-DRB1*1302, HLA-DRB1*1501, 
HLA-DRB3*0301, HLA-DRB4*0101, HLA-DRB5*0101 respectively. The detail 
information of datasets can be found in Table 3. 
MHC Non-binders generation 
Theoretically, an n-mer peptides can lead to 20n possible combinations. Compared to 
these enormous combinations, the limited number of known non-binding peptides is 
much smaller than the total number of the possible combinations, which cannot 
sufficiently represent the entire sequence space. A similar situation happened in proteins 
functional families
24,92
. According to other researchers’ works24,92,93, additional numbers 
of proteins without the specific functions can be created by grouping these pseudo 
proteins into specific domain families and populating the whole protein space by 
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selecting representative proteins from each group of these un-functional families. Such 
kinds of efforts are expected to be applicable for MHC non-binders generation.  
In this work, the additional non-binder peptides were generated from splitting the 
representative protein from each protein family. The steps are outlined as below: 
1) 10082 representative proteins were selected from the 10000+ protein families 
respectively. 
2) Each selected protein has been split into small peptides with different lengths from 8 
amino acids to 25 amino acids. The splitting procedure is shown as below.  
 
3) The peptides were removed from the generated peptides if they were identical to the 
binder peptides from the database. The purpose of this step is to ensure the binding 
peptides were not included in the generated dataset. 472,118 peptides were removed 
from the generated peptides. 78,000,000 peptides were left and can been treated as 
the negative dataset. 
4) Because the generated non-binder dataset is too large to be used in further modeling 
steps, an eligible selection procedure is necessary to be applied to select the 
representative negative dataset from the entire negative dataset. Peptides should be 
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clustered into groups based on their structural and physicochemical feature space. 
Then the representative peptides were randomly selected from each group to form a 
training set that is sufficiently diverse and broadly distributed in the feature space. 
However, due to the large number of generated non-binding peptides in this work, a very 
long time would be needed to cluster 78,000,000 peptides into specific groups, especially 
when each peptide is described using hundreds of descriptors. A classical K-means 
clustering method would take several months to complete the entire clustering process. 
Therefore, as a more simplified clustering method, randomly selection algorithm has 
been applied to select specific number of peptides from each group. Representative 
peptide is randomly selected from each group to form the dataset which is sufficiently 
diverse and equally distributed in the feature space. The representative non-binders have 
been equally selected from different lengths of peptides, from 8-mer to 25-mer, and 
distributed into each allele group, according to a certain ratio of binders to non-binders.  
3.2. Descriptor Generation 
Several descriptors development methods have been designed to construct the feature 
space for peptides 
94,95
. For instance, the peptide sequence can be straightforwardly 
represented by direct sequence of amino acids.  
In this study, as the binders and non-binders datasets were combined by flexible lengths 
of peptides, the straightforward vector representation method would create different 
number of descriptors for each peptide, which is not suitable for following modeling 
procedures. Therefore, a feature representation method with the structural and 
physicochemical properties of a peptide has been developed with a well-formulated 
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procedure. The same number of descriptors can be developed for different lengths of 
peptides by this method. Given the sequence of a peptide, the physical and chemical 
properties, as well as the composition of every constituent amino acid can be computed 
with certain formulas and then generated to be vectors. These computed amino acid 
properties include hydrophobicity, normalized van der Waals volume, polarity, 
polarizability, charge, surface tension, secondary structure, solvent accessibility 
92
 and 
three global composition descriptors: composition, transition and distribution. 
For each of the properties, amino acids can be divided into three or six groups such that 
those in a particular group are regarded to have approximately the same property. For 
instance, charge of amino acid can be divided into three groups: positive (KR), Neutral 
(ANCQGHILMFPSTWYV), and Negative (DE). Secondary structure of amino acid can 
be divided into three groups: Helix (EALMQKRH), Strand (VIYCWFT), and Coil 
(GNPSD). The detailed division of amino acids can be found in Table 1.  
The global composition of amino acids includes three descriptors: composition (C), 
transition (T), and distribution (D), C represents the number of amino acids of a specific 
property divided by the number of total number of amino acids in an entire peptide. T is 
the percent frequency of amino acids with a particular property followed by amino acid 
with different properties. D characters the distribution of the properties along the 
sequence within which the first, 25%, 50%, 75% and 100% of the amino acids of a 
particular property are located respectively. 
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For instance, consider a sequence KRACQTDKDLERWTS. According to the charge 
division in Table 1, the charge descriptor of this peptide is encoded as 
112222313231222.  
Its composition descriptor can be calculated as  
1 2
*100*100 *100





   (19) 
mn  is the number of m in the encoded sequence and N is the length of this sequence. 
According to the example, the number of encoded class “1” is 4, “2” is 8, “3” is 3. The 
composition are 4/15=26.7%, 8/15=53.4% and 3/15=20% respectively. 
Its transition descriptor can be calculated as 
1 3 2 31 2
100 100100
( , , )
1 1 1







,   (20) 
where 21GG , 31GG , and 32GG  are 12, 13, 23 respectively. 1 2
G GT , 1 3G G
T
, 2 3G G
T
 are the 
numbers of dipeptide encoded as 12, 13, 23 respectively in the sequence, T is the length 
of the sequence. 
Its distribution descriptors can be calculated as  
0 25 50 75 100100 100 100 100 100( , , , , )i i i i i
P P P P P
D
N N N N N
    

   (21) 
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There are five distribution descriptors for each encoded number and they describe the 
position percents in the whole sequence for the 0%, 25%, 50%, 75% and 100% residues 
respectively. 
To sum up, there are 20 dimensions of composition descriptors, 51 dimensions of 
hydrophobicity, Van der Waals volume, Polarity, and Polarizability, 21 dimensions of 
Charge, Surface tension, Secondary structure and Solvent accessibility respectively. The 
total number of descriptors is 308. 
 
3.3. Overview of SVM modeling procedure. 
(1) Import the original pre-processed dataset into a matrix. 
(2) Derive physical and chemical features from sequence for each peptide. i.e. 
Hydrophobicity, Volume, and Polarizability etc. 308 descriptors were generated 
for each peptide. 





, the range 
of descriptors is from 0 to 1. 
(4) Randomized the dataset into five subgroups. Held one as the testing set, and rest 
are training sets. Created five training sets and 5 testing sets by this step, as the 
fivefold cross validation. 
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(5) Chosen the appropriate SVM parameters to identify the most suitable model for 
each dataset. 
3.4. Results and Performance evaluation  
 
3.4.1. Self consistency testing accuracy of dataset without generated non-binders 
The 29520 binder peptides and 24848 non-binder peptides downloaded from IEDB have 
been used to run the whole procedure as the sample tests. The average accuracy of the 
test was around 40%, which is shown in Table 2. 
The main reason for this poor result is due to the lack of the clustering. The negative data 
cannot be selected from the entire feature space without the effective clustering. Without 
these negative datasets, the prediction algorithm cannot create an effective model to 
properly distinguish the positive data and negative data.  
3.4.2. Self consistency testing accuracy of dataset with generated non-binders 
Table 3 gives the results of the SVM prediction systems based on the fivefold cross 
validation sets. As shown in the table, the overall accuracies were in the range of 90% to 
99% for all alleles, except the HLA-A*0201 and HLA-DRB1*0101, which were 86.97% 
and 89.24% respectively. The overall accuracies of 30 alleles were above 96%, 7 alleles 
were above 90% and the other 2 alleles were above 85%. These results demonstrated the 




Table 2 Prediction performance of MHC binding peptides without generated 
non-binders. 
SVM parameters Fivefold cross validation performance 
C gamma Sensitivity Specificity Testing Accuracy 
1000 0.1 68.1% 0.4% 37.3% 
1000 0.6 66.3% 4.1% 38.4% 
10000 1.1 52.7% 32.8% 42.8% 
10000 1.6 49.4% 37.9% 44.3% 
100000 2.1 47.8% 37.0% 42.9% 
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Accuracies of 5-fold cross 
validation 
Binders Non-Binders 
HLA-A*0101 452 14225 96.9% 
HLA-A*0201 5015 15091 87.0% 
HLA-A*0202 856 14731 94.5% 
HLA-A*0203 882 14736 94.4% 
HLA-A*0206 796 14919 94.9% 
HLA-A*0301 1176 16300 93.3% 
HLA-A*11 209 6625 96.9% 
HLA-A*1101 1134 15560 91.7% 
HLA-A*2 1274 16993 93.0% 
HLA-A*2601 65 2069 97.0% 
HLA-A*2902 308 9721 96.9% 
HLA-A*3001 324 10241 97.9% 
HLA-A*3002 226 7148 96.9% 
HLA-A*3101 547 17168 96.9% 
HLA-A*3301 209 6624 96.9% 
HLA-A*6801 609 19072 95.7% 
HLA-A*6802 517 16224 93.3% 
HLA-B*0702 488 15350 96.3% 
HLA-B*0801 335 10580 94.3% 
HLA-B*1501 526 16530 96.9% 
HLA-B*3501 454 14307 92.4% 
HLA-B*4402 252 7983 96.3% 
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Accuracies of 5-fold cross 
validation 
Binders Non-Binders 
HLA-DR*1 339 10693 96.7% 
HLA-DR*4 288 9115 96.3% 
HLA-DR*7 254 8047 96.4% 
HLA-DRB1*0101 1993 16527 89.2% 
HLA-DRB1*0301 370 11683 96.9% 
HLA-DRB1*0401 874 16975 95.1% 
HLA-DRB1*0404 270 8542 93.9% 
HLA-DRB1*0405 238 7545 96.9% 
HLA-DRB1*0701 373 11781 96.3% 
HLA-DRB1*0802 240 7604 96.0% 
HLA-DRB1*0901 221 7013 94.5% 
HLA-DRB1*1101 498 15650 96.1% 
HLA-DRB1*1302 236 7479 94.1% 
HLA-DRB1*1501 379 11962 92.9% 
HLA-DRB3*0301 150 4771 95.2% 
HLA-DRB4*0101 254 8052 94.6% 
HLA-DRB5*0101 374 11800 96.9% 
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3.5. Summary and Discussion 
The prediction accuracies of binding peptides by the SVM systems were 90%-96% for 37 
alleles and 86%-89% for 2 alleles, which were much better than the previous model 
which was built using the original datasets. Thus, we can conclude the false binder 
prediction rate is significantly reduced by adding the generated negative datasets. 
It should be noted that the performance of MHC binding prediction might be affected by 
several factors. The first one is the diversity of binding peptide samples. A good 
prediction system cannot be established without adequate samples. Thus higher 
accuracies will be achieved with more MHC binder information. Secondly, the 
imbalanced dataset should be created to represent the entire feature space. A smaller 
number of negative data can lead to reduced accuracy or less diversity.  
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4 METABOLITES SELECTION IN METABONOMICS 
4.1. Data collection and normalization 
The aim of this study was to investigate the role of urinary metabonomics in the 
diagnosis of human bladder cancer and determine the stage of tumor growth. There were 
75 subjects, which included 24 bladder cancer (BC) patients and 51 non-bladder cancer 
(non-BC) subjects in the study. All the urine samples were collected from the 75 subjects 
and stored at -80 °C for further processing. Gas chromatography (GC)/time-of-flight 
(TOF) mass spectrometry has been applied for these urine samples after the serial 
processing of urine preparation. Data acquisition was performed in the full scan mode 
from m/z 40 to 600 with an acquisition rate of 20 spectra/sec. Baseline correction, noise 
reduction, smoothing, library matching and area calculation had been applied for data 
pre-processing of each chromatogram obtained from GC/TOF analysis. Two sets of data 
were produced after data pre-processing: (1) 75 urines samples (24 BC and 51 non-BC) 
with 189 metabolites for each sample. (2) 75 urines samples (24 BC and 51 non-BC) with 
398 metabolites for each sample.  
Normalization is a systematic way of ensuring that a dataset structure is suitable for 
general-purpose querying and free of certain undesirable characteristics. After 
redundancy elimination, data organization and potential data anomalies reduction, the 
biological difference among different samples can be determined and compared using 
machine learning methods. In this study, all the values were derived from the GC/TOF 
chromatogram and processed using the same data pre-processing procedure. Thus 
normalization can be performed for all the samples. 
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Similar to microarray experiments, the major normalization methods for metabonomic 
studies include global normalization performed for all metabolites on the array, and 
housekeeping metabolites normalization using constantly expressed housekeeping/ 
invariant metabolites. The housekeeping normalization method might introduce extra 
potential errors since the metabolites were found to be not expressed constantly. Thus, we 
used global normalization in this study with following procedure. (1) Transforming the 
raw dataset into a two-dimensional matrix. The rows represent different patient samples 
and columns indicate different metabolites detected in patients’ samples. (2) Summing up 
all values for each column. The sum of peak value of each metabolite can be expressed 
by M(i), i represents the number of column. (3) Dividing every row’s value of each 
column by the absolute value of M(i). Then the values of each metabolite can be ranged 
from -1 to +1. Normalization is a key step in the pre-processing of metabonomics data 
and can have a large impact in identifying differential metabolites marks and 
classification for diagnosis. By taking normalization, random or systemic variations, such 
as the influence of detecting efficiencies for each patient’s sample can be well identified 
and removed. Thus the data to be analysed are independent of particular experiment and 
technology used. This can help to avoid the bias caused by variations in sample 
preparation and GC/TOF analysis. The above metabonomics dataset were kindly 
provided by Metabolic Profiling Research Group at NUS Pharmacy. 
 
4.2. Overview of SVM-RFE selection procedure 
We developed a metabolites selection procedure based on algorithm of support vector 
machines (SVM) and the procedure of recursive feature elimination (RFE). An overview 
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of the procedure is shown in Figure 6 and the steps are outlined as below: 
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(1) Import the original pre-processed dataset into a matrix where each row represents 
a sample and each column represents a metabolite. 
(2) Use the random re-sampling method on the dataset matrix for 20 times to generate 
20 groups of training-testing datasets for further analysis. 
(3) Divide each of the 20 groups of training-testing dataset into 500 subgroups, which 
means 500 different sample combinations. 
(4) Use SVM classifier on each training-testing sample combination to determine the 
class of samples (BC or non-BC). 
(5) Use RFE ranking criteria to sequentially rank the importance of each metabolite 
for the SVM classifier. For each group, 500 lists of ranked metabolites will be 
generated. 
(6) Perform the consistency evaluation based on the sequence of metabolites to 
determine the value of contribution. Remove the metabolite with the least 
contribution.  
(7) Iteratively repeat steps (5) and (6) until the SVM classifier achieves highest 
accuracy and no more metabolites can be removed.  
(8) Generate a metabolites list with highest accuracy from the 500 lists of metabolites. 
These metabolites are the biomarkers for the original dataset. 
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(9) Repeat steps (3) to (8) for the rest of 19 groups for the stability evaluation. The 
final selected metabolites will be determined after comparing the results from all 
the 20 groups. 
4.3. Results and Discussion 
4.3.1. Comparison of prediction performance of multiple machine learning 
methods. 
Five machine learning methods, decision tree, Naïve Bayes with kernel function, 
k-nearest neighbor algorithm, neural network and SVM, were used to develop models 
using the dataset with 189 metabolites. The results, given in Table 4, showed that the 
overall accuracies of all the classifiers were in the range of 66.68%-72.76%. According to 
Table 4, the accuracies of KNN and Neural Network are over 75%, which are higher than 
other 3 methods; but the specificity of Neural Network is much lower than KNN’s, which 
only reached 48%. On the other hand, both sensitivity and specificity of KNN are higher 
than 60%, and its AUC is the highest among the five methods. Therefore, KNN can be 
recommended as the best algorithm to build the predict model. However, such 
performance was also much weaker than the model developed by using the metabolites 
selection procedure, which will be further introduced in following sections. The 
differences in performance between the five models are slight and may be due to the fact 
that the choice of metabolites in a model has a stronger influence on the performance 
than the modeling algorithm. 
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Table 4 Prediction performance with metabolites selection for 75 BC samples with 
189 metabolites by multiple machine learning methods. 

































































4.3.2 The predictive performance of identified metabolites biomarkers. 
The predictive performance of models developed using the identified biomarkers are 
given in Tables 5 and 7. For the bladder cancer dataset with 189 metabolites, the 
performance accuracies (Q) were in range of 81.98% - 83.92% and the numbers of 
selected metabolites were in the range of 27 - 35. For the dataset with 398 metabolites, 
the corresponding values are 97.12% - 99.20% and 31 - 55 respectively. The prediction 
performance of the dataset with 398 metabolites outperformed the dataset with 189 
metabolites. Furthermore, analysis of sensitivity (how well cancer patients can be 
detected) and specificity (how well controls can be detected) suggested the dataset with 
398 metabolites had a better balance between sensitivity and specificity. 
The results also show a good stability in the overall accuracy. For example, in Table 7, 
the difference between the different trials is less than 2.1%. This is mainly due to two 
reasons. Firstly, the globally optimized parameters were determined using grid search and 
thus the best classification accuracy over multi-time modeling and testing steps can be 
found. Secondly, the additional metabolites ranking evaluation on top of the normal RFE 




Table 5 Overall prediction accuracies of 20 times SVM-RFE selection for 75 BC 






Overall performance in 500 testing datasets 
Sensitivity Specificity Q 
1 32 58.61% 95.43% 83.11% 
2 35 57.94% 96.13% 83.32% 
3 34 59.21% 95.68% 83.41% 
4 28 58.01% 96.34% 83.50% 
5 33 56.92% 95.67% 82.45% 
6 27 57.39% 96.07% 83.12% 
7 27 58.97% 96.12% 83.68% 
8 29 57.08% 95.43% 82.50% 
9 27 56.97% 96.39% 83.16% 
10 30 56.23% 95.71% 82.37% 
11 33 57.55% 95.42% 82.70% 
12 28 58.25% 96.07% 83.40% 
13 32 58.50% 95.85% 83.24% 
14 34 56.59% 94.81% 81.98% 
15 28 57.58% 96.42% 83.42% 
16 33 60.17% 95.52% 83.67% 
17 29 60.67% 95.69% 83.92% 
18 31 57.73% 95.95% 83.11% 
19 28 57.65% 96.02% 83.15% 
20 27 57.12% 96.47% 83.17% 
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Metabolite ID lists 
1 32 3, 13, 15, 17, 23, 38, 41, 47, 53, 54, 66, 81, 84, 85, 86, 90, 94, 102, 108, 120, 125, 144, 156, 165, 166, 172, 175, 176, 181, 182, 183, 186 
2 35 3, 13, 14, 15, 17, 23, 25, 26, 38, 41, 47, 53, 54, 66, 81, 84, 85, 86, 90, 94, 102, 120, 125, 126, 144, 156, 165, 166, 172, 175, 176, 181, 182, 183, 186 
3 34 3, 13, 14, 15, 17, 23, 25, 26, 38, 41, 47, 53, 54, 66, 81, 84, 85, 86, 90, 94, 102, 120, 125, 126, 144, 156, 165, 166, 175, 176, 181, 182, 183, 186 
4 28 15, 17, 23, 26, 38, 41, 47, 53, 54, 66, 81, 84, 85, 86, 94, 102, 120, 125, 144, 165, 166, 172, 175, 176, 181, 182, 183, 186 
5 33 3, 15, 17, 23, 25, 26, 38, 41, 47, 53, 54, 66, 81, 84, 85, 86, 90, 94, 102, 108, 120, 125, 144, 156, 165, 166, 172, 175, 176, 181, 182, 183, 186 
6 27 3, 14, 17, 23, 26, 38, 41, 47, 53, 54, 66, 81, 85, 86, 94, 102, 108, 120, 125, 144, 165, 166, 175, 176, 181, 182, 183 
7 27 13, 15, 17, 23, 38, 41, 47, 54, 57, 66, 81, 85, 86, 90, 94, 102, 120, 125, 126, 144, 166, 175, 176, 181, 182, 183, 186 
8 29 13, 17, 23, 36, 38, 47, 53, 54, 57, 66, 81, 85, 86, 90, 94, 102, 119, 120, 125, 126, 144, 166, 172, 175, 176, 181, 182, 183, 186 
9 27 10, 13, 17, 23, 38, 41, 47, 53, 54, 66, 81, 85, 86, 90, 94, 102, 120, 125, 126, 144, 165, 166, 175, 176, 181, 182, 186 
10 30 13, 17, 23, 36, 38, 41, 47, 53, 54, 57, 66, 81, 85, 86, 90, 94, 102, 120, 125, 126, 144, 165, 166, 172, 175, 176, 181, 182, 183, 186 
11 33 3, 15, 17, 23, 25, 26, 38, 41, 47, 53, 54, 66, 81, 84, 85, 86, 90, 94, 102, 108, 120, 125, 144, 156, 165, 166, 172, 175, 176, 181, 182, 183, 186 
12 28 13, 15, 17, 23, 26, 38, 41, 47, 53, 54, 66, 81, 85, 86, 90, 94, 102, 120, 125, 126, 144, 166, 175, 176, 181, 182, 183, 186 
13 32 3, 14, 15, 17, 23, 25, 26, 38, 41, 47, 66, 76, 81, 84, 85, 86, 90, 94, 102, 120, 125, 126, 144, 156, 165, 166, 175, 176, 181, 182, 183, 186 
14 34 3, 13, 15, 17, 23, 25, 38, 41, 47, 53, 54, 66, 71, 81, 84, 85, 86, 90, 94, 102, 108, 119, 120, 125, 144, 156, 166, 172, 175, 176, 181, 182, 183, 186 
15 28 3, 13, 17, 23, 38, 41, 47, 53, 54, 66, 81, 85, 86, 94, 102, 120, 125, 126, 144, 165, 166, 172, 175, 176, 181, 182, 183, 186 
16 33 3, 13, 15, 17, 23, 25, 26, 38, 41, 47, 54, 66, 81, 84, 85, 86, 90, 94, 102, 120, 125, 126, 144, 156, 165, 166, 172, 175, 176, 181, 182, 183, 186 
17 29 3, 4, 17, 23, 26, 36, 38, 47, 54, 66, 81, 84, 85, 86, 90, 94, 102, 120, 125, 126, 144, 165, 166, 175, 176, 181, 182, 183, 186 
18 31 3, 13, 14, 17, 23, 25, 26, 38, 41, 47, 53, 54, 66, 81, 85, 86, 94, 102, 120, 125, 126, 144, 165, 166, 172, 175, 176, 181, 182, 183, 186 
19 28 10, 13, 15, 17, 23, 25, 38, 47, 54, 66, 81, 84, 85, 86, 90, 102, 119, 120, 125, 126, 144, 165, 166, 175, 176, 181, 182, 186 
20 27 3, 17, 23, 26, 38, 41, 47, 53, 54, 66, 81, 85, 86, 94, 102, 120, 125, 126, 144, 165, 166, 175, 176, 181, 182, 183, 186 
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Table 7 Overall prediction accuracies of 20 times SVM-RFE selection for 75 BC 






Overall performance in 500 testing datasets 
Sensitivity Specificity Q 
1 36 98.61% 99.42% 98.88% 
2 34 98.88% 99.86% 99.20% 
3 35 97.60% 99.60% 98.26% 
4 55 98.26% 99.76% 98.76% 
5 34 98.33% 99.75% 98.80% 
6 37 98.03% 99.83% 98.62% 
7 33 97.53% 99.30% 98.11% 
8 47 96.67% 99.53% 97.62% 
9 38 97.08% 99.88% 97.99% 
10 36 95.85% 99.68% 97.12% 
11 54 98.14% 99.83% 98.70% 
12 36 97.87% 99.75% 98.48% 
13 39 96.30% 99.56% 97.37% 
14 43 98.48% 99.63% 98.86% 
15 31 97.87% 99.71% 98.47% 
16 46 97.23% 99.36% 97.92% 
17 52 97.01% 99.86% 97.94% 
18 55 98.34% 99.97% 98.87% 
19 32 98.74% 99.90% 99.12% 
20 37 97.46% 98.87% 97.92% 
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Metabolite ID lists 
1 36 68, 72, 104, 105, 106, 107, 108, 116, 127, 149, 150, 152, 163, 180, 188, 193, 217, 230, 249, 250, 256, 262, 266, 284, 287, 288, 299, 302, 304, 316, 350, 352, 354, 365, 371, 382 
2 34 61, 68, 72, 104, 105, 106, 107, 108, 115, 116, 127, 149, 150, 152, 163, 180, 188, 217, 230, 249, 250, 256, 266, 284, 287, 288, 302, 304, 316, 350, 352, 365, 371, 382 
3 35 46, 61, 68, 72, 104, 105, 106, 107, 108, 116, 127, 149, 150, 152, 179, 180, 188, 217, 230, 249, 250, 256, 266, 284, 287, 288, 302, 304, 316, 350, 352, 365, 371, 382, 388 
4 55 
46, 61, 68, 72, 75, 97, 104, 105, 106, 107, 108, 116, 124, 127, 132, 133, 135, 149, 150, 152, 163, 179, 180, 184, 188, 210, 217, 218, 230, 234, 249, 250, 252, 256, 262, 266, 284, 
287, 288, 289, 291, 299, 302, 304, 316, 350, 352, 354, 360, 363, 365, 368, 371, 382, 388 
5 34 24, 61, 72, 104, 105, 106, 107, 108, 116, 127, 149, 150, 152, 179, 180, 188, 217, 230, 249, 250, 256, 266, 287, 288, 291, 302, 304, 316, 350, 352, 354, 365, 371, 382 
6 37 46, 61, 68, 72, 97, 104, 105, 106, 107, 108, 115, 116, 127, 149, 150, 152, 163, 180, 188, 217, 230, 249, 250, 256, 266, 284, 287, 288, 299, 302, 304, 316, 350, 352, 365, 371, 382 
7 33 46, 61, 68, 72, 105, 106, 107, 108, 116, 127, 149, 150, 152, 179, 180, 188, 217, 230, 249, 250, 256, 266, 284, 287, 288, 302, 304, 316, 350, 352, 365, 371, 382 
8 47 
3, 46, 61, 68, 72, 75, 97, 104, 105, 106, 107, 108, 116, 124, 127, 133, 149, 150, 152, 163, 179, 188, 217, 230, 249, 250, 252, 256, 262, 266, 284, 287, 288, 291, 299, 302, 304, 316, 
350, 352, 354, 360, 363, 365, 371, 382, 388 
9 38 
24, 46, 61, 68, 72, 97, 104, 105, 106, 107, 108, 116, 127, 149, 150, 152, 163, 180, 188, 217, 230, 249, 250, 256, 262, 266, 284, 287, 288, 299, 302, 304, 316, 350, 352, 365, 371, 
382 
10 36 46, 61, 68, 72, 97, 104, 105, 106, 107, 108, 116, 127, 149, 152, 180, 188, 210, 217, 230, 249, 250, 256, 266, 284, 287, 288, 291, 299, 302, 304, 316, 350, 352, 365, 371, 382 
11 54 
46, 61, 68, 72, 75, 89, 97, 104, 105, 106, 107, 108, 115, 116, 124, 127, 132, 133, 149, 150, 152, 179, 180, 184, 188, 202, 217, 218, 230, 234, 249, 250, 252, 256, 262, 266, 284, 287, 
288, 292, 294, 299, 302, 304, 316, 350, 352, 360, 363, 365, 368, 371, 382, 388 
12 36 61, 72, 75, 104, 105, 106, 107, 108, 115, 116, 127, 149, 150, 152, 179, 180, 188, 217, 230, 249, 250, 256, 266, 287, 288, 291, 302, 316, 350, 352, 360, 363, 365, 371, 382, 388 
13 39 
46, 61, 68, 72, 75, 97, 104, 105, 106, 107, 108, 116, 124, 127, 149, 152, 179, 180, 188, 217, 230, 249, 250, 256, 262, 266, 287, 288, 302, 316, 350, 352, 360, 363, 365, 368, 371, 
382, 388 
14 43 
46, 61, 68, 72, 75, 97, 104, 105, 106, 107, 108, 116, 124, 127, 149, 150, 152, 163, 179, 180, 188, 217, 230, 249, 250, 256, 262, 266, 287, 288, 291, 299, 302, 304, 316, 350, 352, 
354, 360, 363, 365, 371, 382 
15 31 24, 61, 72, 104, 105, 106, 107, 116, 127, 149, 150, 152, 179, 180, 188, 217, 230, 249, 250, 256, 266, 287, 288, 302, 316, 350, 352, 354, 363, 371, 382 
16 46 
46, 61, 68, 72, 75, 89, 97, 104, 105, 106, 107, 108, 115, 116, 127, 133, 149, 150, 152, 179, 184, 188, 217, 230, 234, 249, 250, 256, 262, 266, 284, 287, 288, 294, 299, 302, 304, 316, 
350, 352, 360, 363, 365, 368, 371, 382 
17 52 
46, 61, 68, 72, 84, 89, 97, 104, 105, 106, 107, 108, 115, 116, 124, 127, 133, 148, 149, 150, 152, 163, 179, 180, 188, 202, 217, 230, 249, 250, 252, 256, 262, 266, 284, 287, 288, 291, 
292, 299, 302, 304, 316, 350, 352, 354, 360, 363, 365, 371, 382, 388 
18 55 
3, 46, 61, 68, 72, 75, 84, 89, 97, 104, 105, 106, 107, 108, 115, 116, 127, 132, 133, 149, 150, 152, 163, 179, 180, 188, 193, 202, 217, 218, 230, 234, 249, 250, 256, 262, 266, 284, 
287, 288, 291, 294, 299, 302, 304, 316, 350, 352, 360, 363, 365, 371, 378, 382, 388 
19 32 61, 72, 104, 105, 106, 107, 108, 115, 116, 127, 149, 150, 152, 180, 188, 217, 228, 230, 249, 250, 256, 266, 284, 287, 288, 302, 304, 316, 350, 352, 371, 382 




4.3.3. The list of selected metabolite biomarkers 
Tables 6 and 8 show the ID list of the selected metabolite biomarkers for two datasets. 
For the dataset with 189 metabolites, 27-35 metabolites were identified as the biomarkers 
for the bladder cancer. The median number of chosen biomarkers was 29 and the stability 
was also adequate enough. For the dataset with 398 metabolites, 31-55 biomarkers were 
chosen. Furthermore, the IDs of metabolites chosen by each time are similar. 31 
metabolites were identified in at least 16 out of the 20 experiments. The ID and name of 
these metabolites are listed in Table 9.  
To further analyze the biological meaning of these selected biomarkers, it is necessary to 
understand their functions in metabolic pathway network and the relationship between 
these metabolites and the mechanism of bladder cancer. Several steps need to be 
performed for such purpose. Firstly, the structures of the selected metabolites should be 
derived from their chemical compound names, which are illustrated in Table 10. Secondly, 
determine the chemical and biological information about this compound. It can be 
achieved by querying online chemical compounds resources such as PubChem and 
ChEMBL, as well as analyzing designed experiments. Once the chemical and biological 
properties of these compounds are clear, the next steps is to identify the roles of these 
marker metabolites in related metabolic pathways by building the model of pathway 
networks for them. These steps will be gradually accomplished in further studies. 
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Table 9 List of 31 Selected metabolites (repeated rate > 80%) for 75 BC samples 
with 398 metabolites 
ID of selected metabolite 
biomarker 
Name of selected metabolite biomarker 
61 Silane, trimethyl(phenylmethoxy) 
68 Butanoic acid, 4-[bis(trimethylsilyl)amino]-, trimethylsilyl ester 
72 Silane, tetramethyl- 
104 Silanamine, 
1,1,1-trimethyl-N-(trimethylsilyl)-N-[2-[(trimethylsilyl)oxy]ethyl]- 
105 Trimethylsilyl ether of glycerol 
106 Tetradecane 
107 Ethyl aminomalonate bis-(trimethylsilyl)- deriv. 
116 Acetic acid, bis[(trimethylsilyl)oxyl]-, trimethylsilyl ester 
127 Propanoic acid, 2,3-bis[(trimethylsilyl)oxy]-, trimethylsilyl ester 
149 1,3-Cyclopentadiene, 5,5-dimethyl-1-(trimethylsilylmethyl)- 
150 Butane, 2,3-bis(trimethylsiloxy)- 
152 N,O,O-Tris(trimethylsilyl)-L-threonine 
179 Glycine, N-formyl-N-(trimethylsilyl)-, trimethylsilyl ester 
180 Propanoic acid, 3-[bis(trimethylsilyl)amino]-2-methyl-, 
trimethylsilyl ester 
188 cis-4-Trimethylsilyloxy-cyclohexyl(trimethylsilyl)carboxylate 
217 Pentanedioic acid, 3-methyl-3-[(trimethylsilyl)oxy]-, 
bis(trimethylsilyl) ester 
230 3-Ketovaleric acid, bis(trimethylsilyl)- 
249 Analyte 473 (1) 
250 Analyte 473 (2) 




Continued Table 9 
 
ID of selected metabolite 
biomarker 
Name of selected metabolite biomarker 
266 Ribitol, 1,2,3,4,5-pentakis-O-(trimethylsilyl)- 
284 Heptasiloxane, 1,1,3,3,5,5,7,7,9,9,11,11,13,13-tetradecamethyl- 
287 Tyrosine, O-trimethylsilyl-, trimethylsilyl ester 
288 Glycine, N-benzoyl-, trimethylsilyl ester 
302 D-Galactose-MOX-TMS-peak2 
304 Acrylic acid, 2,3-bis[(trimethylsilyl)oxy]-, trimethylsilyl ester 
316 
D-Gluconic acid, 2,3,4,5,6-pentakis-O-(trimethylsilyl)-, 
trimethylsilyl ester 
350 Mercaptoacetic acid, bis(trimethylsilyl)- 
352 Analyte 1023 











Name of selected 
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230 3-Ketovaleric acid, 
bis(trimethylsilyl)- 
 
249 Analyte 473 N.A. 
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trimethylsilyl ester 
 



















350 Mercaptoacetic acid, 
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352 Analyte 1023 N.A. 










4.3.4. Performance evaluation with multiple classifiers 
In order to evaluate the performance of the selected biomarkers, multiple classification 
models had been built to re-train the datasets with the selected metabolites. The 
performance of these models can be found from the Table 11. As shown in Table 11, 
overall accuracies of all classifiers were above 79%, in particular, the accuracy of Naïve 
Bayes (kernel) and the accuracy of SVM were above 90%. Sensitivity values of all 
classifiers were above 92%, except for decision tree classifier. Specificity values of these 
classifiers were not as high as the sensitivity values. However, all of them were above 
75%, except for KNN classifier. The performance of these classifiers suggests that the 
selected metabolites were representative of the original data. Moreover, these selected 




Table 11 List of evaluation performance of the 31 Selected metabolites (repeated 





























































5. CONCLUSION AND FUTURE WORK 
Accurate identification of peptides binding to specific MHC molecules is fundamental for 
understanding the mechanisms of both humoral and adaptive immunity, and important for 
developing effective epitope-based vaccines for immunotherapy of infectious, 
autoimmune, and cancer diseases. Experimental methods for identifying MHC binding 
peptides are costly and time-consuming. In-silico methods have thus been explored for 
facilitating epitope screening to complement laboratory experiments in reducing the cost 
and time for vaccine design. In this study, we showed that MHC binding prediction 
methods were able to predict MHC binding peptides with high accuracy. The method 
developed here can be used to identify promising candidate epitopes for further 
experimental verification. 
In the MHC binding peptide prediction study, the performances of prediction systems 
were compared between the original datasets and datasets with the generated non-binding 
peptides. It was found that the separated datasets by alleles with the generated 
non-binding peptides works much more effectively than the original dataset. The positive 
accuracies showing the percentage of the correctly predicted known binding peptides 
have a high level of precision. Based on the principle of the SVM algorithm, SVM shows 
good performance when the samples could sufficiently represent the whole space. 
Therefore, the diversity and representative ability of datasets are the major concerns of 
SVM prediction system. Although certain extent of evaluation have been made for the 
SVM prediction system, further validation is still necessary. Independent evaluations by 
new experimental samples and screening with specific genome could be appropriate ways 
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to validate this MHC-binding prediction system.  
Metabonomics investigation on urine samples of bladder cancer patients could lead to an 
overview of the metabolic disturbances taking place in the patients, which is essential for 
the understanding of physiological progress of bladder cancer. This study demonstrates a 
feasible way of metabonomics research by selecting metabolites markers for specific 
disease. GC/TOF mass spectrometry is the major analytical techniques, which played 
important role in deriving data from biological sample, the feature selection algorithm; 
SVM-RFE has been applied to select the discriminative and meaningful metabolites from 
the metabolic profiling data. The result of feature selection achieved an average 
classification accuracy rate of 98.35%, which indicated the metabolites selection by 
SVM-RFE could discriminate well among and are biologically meaningful for 
metabonomics studies. 
To further evaluate the identified metabolite biomarkers of bladder cancer diagnosis, 
several steps should be performed. Firstly, because the significant improvement of 
performance accuracy was achieved when SVM-RFE metabolites selection procedure 
was applied, and when comparing with other machine learning algorithms without 
metabolites selection, SVM did not show obvious advantage, we believe that as an 
effective way to select the appropriated feature, recursive feature elimination can be 
combined with the other machine learning methods, such as neural network, genetic 
algorithm and k nearest neighbor, to develop several new RFE procedures. 
Secondly, we can further analysis the selected 31 metabolite biomarkers for bladder 
cancer by unsupervised algorithms, such as PCA. Since these biomarkers showed high 
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accuracies when tested by SVM classifier, they should show good distinction abilities 
when analyzed using PCA. The PCA score plot and loading plot can be drawn to 
determine how well these biomarkers can separate the bladder cancer samples and 
non-bladder cancer controls. 
Thirdly, we can further interpret the biological relations of identified biomarkers with 
bladder cancer. The metabolite pathway of bladder cancer could be complicated and 
related to the physiological and biochemical properties of certain cells, organs and entire 
human system. Thus, it is necessary to investigate roles of biomarkers and highlighted 
metabolites in whole metabolic pathway networks, for better understanding of the 
pathway network profile and even improving the network modeling. Currently, there are 
several metabolic pathway resources for further investigation of metabonomics studies 
and reconstructing metabolic models, such as Kyoto Encyclopedia of Genes and 
Genomes (KEGG), BioCyc, EcoCyc, and MetaCyc  
Fourthly, since our SVM-RFE method exhibited good performances for metabolites 
selection of bladder cancer, we can investigate the metabonomics dataset of other types 
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